Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), Dongfang Electric (01072), and COSCO Shipping Holdings (01919), with short ratios of 18.64%, 17.51%, and 16.68% respectively [1][2] - The company with the largest increase in short positions is Dongfang Electric (01072), which saw an increase of 2.20% from the previous short ratio [1][2] - The companies with the largest decrease in short positions include Sanhua Intelligent Control (02050), Tianqi Lithium (09696), and Yuejiang (02432), with decreases of -1.42%, -0.82%, and -0.71% respectively [1][3] Group 2 - The latest short position data shows that Vanke Enterprises has 411 million shares shorted, while Dongfang Electric has 71.45 million shares, and COSCO Shipping Holdings has 480 million shares shorted [2] - The companies with the largest increases in short positions also include JAKS Resources B (01167) and CSPC Pharmaceutical Group (01093), with increases of 0.77% and 0.56% respectively [2] - The companies with the largest decreases in short positions also include Ganfeng Lithium (01772) and Sunac China (01918), with decreases of -0.68% and -0.55% respectively [3][4]

Market Overview - The Hong Kong stock market opened slightly lower on December 31, with the Hang Seng Index down 0.21% at 25,801.49 points, the Hang Seng Tech Index down 0.22% at 5,566.24 points, and the National Enterprises Index down 0.23% at 8,970.49 points [1] - Major tech stocks mostly declined, with Alibaba down 0.55%, Tencent down 0.42%, and JD.com down 1.32%. Conversely, Xiaomi rose by 0.86% [1] Company News - Zijin Mining (02899.HK) expects to achieve a net profit of approximately RMB 51-52 billion for the fiscal year 2025, representing a year-on-year increase of about 59%-62% due to increased production and sales prices [2] - Starry Development (00640.HK) reported revenue of approximately HKD 835 million for the fiscal year ending September 30, 2025, a year-on-year increase of 13.4%, and a net profit of approximately HKD 122 million, up 21.7% [2] - Shanghai Electric (02727.HK) plans to sell a 47.4% stake in Electric Guoxuan and waive its preemptive rights to an additional 3.6% stake [3] - CNOOC Services (02883.HK) has recently purchased bank wealth management products totaling HKD 3 billion [4] Clinical Trials and Drug Approvals - Fosun Pharma (02196.HK) has initiated clinical trials for its integrated diagnosis and treatment nuclear medicine project SRT-007 within China [5] - Hutchison China MediTech (00013.HK) announced that its new drug application for Savolitinib, intended for treating gastric cancer patients with MET amplification, has been accepted and prioritized for review [5] Strategic Partnerships - Linkong Biotechnology Group (00690.HK) has established a strategic partnership with Wenzhou Medical University National Engineering Research Center and the Ouhai District People's Government [6] Financing Activities - Youlian International Education Leasing (01563.HK) has entered into a financing lease agreement for energy-saving equipment [7] Stock Buybacks - Tencent Holdings (00700.HK) repurchased 1.062 million shares for HKD 636 million at prices ranging from HKD 594.5 to HKD 600.5 [8] - COSCO Shipping Holdings (01919.HK) repurchased 4.3715 million shares for HKD 61.05 million at prices between HKD 13.86 and HKD 14.06 [9] - China Feihe (06186.HK) repurchased 8.837 million shares for HKD 36.34 million at prices between HKD 4.07 and HKD 4.12 [10] - Kuaishou-W (01024.HK) repurchased approximately 464,000 shares for HKD 29.88 million at prices between HKD 63.75 and HKD 64.75 [10] - Giant Bio (02367.HK) repurchased 400,000 shares for HKD 13.44 million at prices between HKD 33.48 and HKD 33.76 [11] Institutional Insights - Everbright Securities notes that the overall profitability of Hong Kong stocks remains strong, with relatively scarce assets in internet, new consumption, and innovative pharmaceuticals. Despite recent gains, valuations are still considered low, suggesting long-term investment potential [12] - Founder Securities highlights positive signals from government policies aimed at optimizing the "two new" policies, which may enhance the competitive environment in the automotive industry [12] - CITIC Securities anticipates a 7.9% increase in Hong Kong private residential transaction volumes in 2026, driven by a favorable interest rate environment and increased asset allocation demand [12]

证券时报·数据宝统计，巨子生物在港交所公告显示，12月30日以每股33.480港元至33.760港元的价格回 购40.00万股，回购金额达1344.08万港元。该股当日收盘价33.540港元，下跌2.95%，全天成交额3.85亿 港元。 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.12.30 | 40.00 | 33.760 | 33.480 | 1344.08 | | 2025.12.29 | 40.00 | 34.760 | 34.280 | 1381.44 | | 2025.12.23 | 40.00 | 36.480 | 35.740 | 1439.66 | | 2025.12.22 | 40.00 | 36.340 | 35.860 | 1442.97 | | 2025.12.19 | 40.00 | 35.520 | 34.540 | 1405.36 | | 2025.12.18 | 40.00 | 35.040 | 34.420 | 1388.30 | | ...

智通财经APP讯，巨子生物(02367)发布公告，该公司于2025年12月30日斥资1344.08万港元回购40万股 股份，每股回购价格为33.48-33.76港元。 ...

巨子生物(02367)发布公告，该公司于2025年12月30日斥资1344.08万港元回购40万股股份，每股回购价 格为33.48-33.76港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2025年12月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

每经AI快讯，巨子生物(02367.HK)午后跌超3%，截至发稿，跌2.95%，报33.54港元，成交额2.46亿港 元。 ...

该行指，巨子生物的投资逻辑已由增长转向战略调整，该行认为当前尚缺乏明显的反弹催化剂。在企稳 迹象更加明朗之前，持观望态度。该行将2025-27年收入预测平均下调30%，以反映管理层最新指引及 该行对2026年更加审慎的展望。该行将销售费用率预测从36%上调至38%，以反映调整阶段下的执行挑 战。目标价基于由原来的2026年预测市盈率21.5倍降至16倍。 招商证券国际发布研报称，将巨子生物评级由"增持"下调至"中性"，将目标价从64港元下调45%至35港 元。报告指，公司正面临诸多挑战，包括一系列声誉危机，以及核心品牌可复美在双11大促期间出现两 位数下滑。虽然该行认为公司股价已基本消化相关问题及随后下调2025年销售指引，但该行对2026年前 景仍持谨慎态度。该行认为，当前市场一致预期可能过于乐观。 巨子生物(02367)午后跌超3%，截至发稿，跌2.95%，报33.54港元，成交额2.46亿港元。 ...

智通财经APP获悉，巨子生物(02367)午后跌超3%，截至发稿，跌2.95%，报33.54港元，成交额2.46亿港 元。 该行指，巨子生物的投资逻辑已由增长转向战略调整，该行认为当前尚缺乏明显的反弹催化剂。在企稳 迹象更加明朗之前，持观望态度。该行将2025-27年收入预测平均下调30%，以反映管理层最新指引及 该行对2026年更加审慎的展望。该行将销售费用率预测从36%上调至38%，以反映调整阶段下的执行挑 战。目标价基于由原来的2026年预测市盈率21.5倍降至16倍。 招商证券国际发布研报称，将巨子生物评级由"增持"下调至"中性"，将目标价从64港元下调45%至35港 元。报告指，公司正面临诸多挑战，包括一系列声誉危机，以及核心品牌可复美在双11大促期间出现两 位数下滑。虽然该行认为公司股价已基本消化相关问题及随后下调2025年销售指引，但该行对2026年前 景仍持谨慎态度。该行认为，当前市场一致预期可能过于乐观。 ...

Summary of Key Points Core Viewpoint - On December 29, 55 Hong Kong-listed companies conducted share buybacks, totaling 37.9 million shares and an aggregate amount of HKD 999 million [1][2]. Group 1: Major Companies Involved in Buybacks - Tencent Holdings repurchased 1.057 million shares for HKD 636 million, with a yearly total buyback amount of HKD 78.765 billion [1][2]. - Xiaomi Group-W bought back 3.9 million shares for HKD 151 million, with a total buyback amount of HKD 6.136 billion for the year [1][2]. - China COSCO Shipping Holdings repurchased 3.46 million shares for HKD 47.9 million, with a total buyback amount of HKD 6.866 billion for the year [1][2]. Group 2: Buyback Statistics - The highest buyback amount on December 29 was from Tencent Holdings at HKD 636 million, followed by Xiaomi Group-W at HKD 151 million [1][2]. - The largest number of shares repurchased on December 29 was by Four Seasons Medicine, with 8 million shares, followed by Xiaomi Group-W and China COSCO Shipping Holdings with 3.9 million and 3.46 million shares, respectively [1][2]. Group 3: Additional Companies and Their Buyback Data - Kingsoft repurchased 713,600 shares for HKD 20 million, with a total buyback amount of HKD 33.465 million for the year [2]. - Kuaishou-W bought back 310,000 shares for HKD 20 million, with a total buyback amount of HKD 306.840 million for the year [2]. - Other notable companies include Miniso Group, which repurchased 320,600 shares for HKD 1.195 million, and Four Seasons Medicine, which had a total buyback amount of HKD 15.332 million for the year [2][3].